Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackman, R. J.
Right arrow Articles by Adler, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackman, R. J.
Right arrow Articles by Adler, S. J.
(Radiology. 2001;218:497-502.)
© RSNA, 2001


Breast Imaging

Stereotactic Breast Biopsy of Nonpalpable Lesions: Determinants of Ductal Carcinoma in Situ Underestimation Rates1

Roger J. Jackman, MD, Fred Burbank, MD, Steve H. Parker, MD, W. Phil Evans, III, MD, Mary C. Lechner, MD, Thomas R. Richardson, MD, Anne A. Smid, MD, Harriet B. Borofsky, MD, Carol H. Lee, MD, Harvey M. Goldstein, MD, Kathy J. Schilling, MD, Alan B. Wray, MD, Rachel F. Brem, MD, Thomas H. Helbich, MD, Daniel E. Lehrer, MD and Steven J. Adler, MD

1 From the Depts of Radiology of Palo Alto Med Clinic, 795 El Camino Real, Palo Alto, CA 94301 (R.J.J.); Mission Breast Care Center, Mission Viejo, Calif (F.B.); Sally Jobe Breast Center, Englewood, Colo (S.H.P.); Susan G. Komen Breast Center, Dallas, Tex (W.P.E.); Park Nicollet Med Center, Minneapolis, Minn (M.C.L.); Fresno Breast Center, Calif (T.R.R.); Women’s Center Breast Care Clinic of Cox Health Systems, Springfield, Mo (A.A.S.); Mills-Peninsula Breast Center, San Mateo, Calif (H.B.B.); Yale Univ School of Medicine, New Haven, Conn (C.H.L.); South Texas Radiology Group, San Antonio (H.M.G.); Boca Raton Community Hosp, Fla (K.J.S.); Eastern Idaho Regional Med Center, Idaho Falls (A.B.W.); Johns Hopkins Med Institutions, Baltimore, Md (R.F.B.); Univ of Vienna, Austria (T.H.H.); CERIM, Buenos Aires, Argentina (D.E.L.); and Virginia Mason Med Center, Seattle, Wash (S.J.A.). From the 1998 RSNA scientific assembly. Received Aug 19, 1999; revision requested Oct 14; final revision received May 2, 2000; accepted May 22. Supported in part by an educational grant from Biopsys Medical to the Palo Alto Medical Foundation. Address correspondence to R.J.J. (e-mail: jackmanr@pamf.org).


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
PURPOSE: To measure the effect of biopsy device, probe size, mammographic lesion type, lesion size, and number of samples obtained per lesion on the ductal carcinoma in situ (DCIS) underestimation rate.

MATERIALS AND METHODS: Nonpalpable breast lesions at 16 institutions received a histologic diagnosis of DCIS after 14-gauge automated large-core biopsy in 373 lesions and after 14- or 11-gauge directional vacuum-assisted biopsy in 953 lesions. The presence of histopathologic invasive carcinoma was noted at subsequent surgical biopsy.

RESULTS: By performing the {chi}2 test, independent significant DCIS underestimation rates by biopsy device were 20.4% (76 of 373) of lesions diagnosed at large-core biopsy and 11.2% (107 of 953) of lesions diagnosed at vacuum-assisted biopsy (P < .001); by lesion type, 24.3% (35 of 144) of masses and 12.5% (148 of 1,182) of microcalcifications (P < .001); and by number of specimens per lesion, 17.5% (88 of 502) with 10 or fewer specimens and 11.5% (92 of 799) with greater than 10 (P < .02). DCIS underestimations increased with lesion size.

CONCLUSION: DCIS underestimations were 1.9 times more frequent with masses than with calcifications, 1.8 times more frequent with large-core biopsy than with vacuum-assisted biopsy, and 1.5 times more frequent with 10 or fewer specimens per lesion than with more than 10 specimens per lesion.

Index terms: Biopsies, technology, 00.1261, 00.1262 • Breast, biopsy, 00.1261, 00.1262 • Breast, diseases, 00.324, 00.719 • Breast, ducts, 00.324, 00.719 • Breast neoplasms, diagnosis, 00.126, 00.324, 00.719


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
When ductal carcinoma in situ (DCIS) without associated invasive carcinoma is diagnosed at stereotactic percutaneous biopsy of nonpalpable breast lesions with the patient in a prone position and with the use of a 14-gauge automated large-core needle (hereafter, large-core biopsy), subsequent surgery will help to detect invasive carcinoma at the same site in 15%–36% of lesions (18). We consider the large-core biopsy diagnosis to be both a true-positive finding (for the presence of carcinoma) and a "histologic underestimation" (for the severity of the carcinoma) (9). Because axillary node dissection is usually not performed for DCIS (1014), a percutaneous biopsy–based DCIS underestimation can result in axillary node dissection at a later date and thus a two-stage therapeutic surgical procedure. A lower DCIS underestimation rate is desirable.

A newer percutaneous biopsy technique—directional vacuum-assisted biopsy (hereafter, vacuum-assisted biopsy)—enables the extraction of more tissue more contiguously than does biopsy with a large-core needle (15,16). The vacuum-assisted device can be used with either 14- or 11-gauge probes.

We performed this multiinstitutional study to measure the effect of biopsy device, probe size, mammographic lesion type, lesion size, and number of samples obtained per lesion on the DCIS underestimation rate.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In 13,640 nonpalpable breast lesions (5,334 mass lesions and 8,306 microcalcification lesions) in which stereotactic percutaneous biopsy with the patient in a prone position was performed at 16 institutions, a histologic diagnosis of carcinoma was made at biopsy in 2,789 (20.4%) lesions; 1,397 (10.2%) of the lesions were diagnosed as invasive carcinoma (with or without associated DCIS) at biopsy, and 1,392 (10.2%) of the lesions were diagnosed as DCIS (without associated invasive carcinoma) at biopsy. Of the 1,392 DCIS lesions, 57 (4.1%) were lost to follow-up and nine (0.6%) did not result in surgery. Thus, a diagnosis of DCIS (without associated invasive carcinoma) was made in 1,326 (9.7%) lesions in which surgery was subsequently performed (Table 1). Those 1,326 lesions (144 mass lesions and 1,182 microcalcification lesions) are the subject of this article. Surgical histologic findings were compared for the presence or absence of invasive breast carcinoma.


View this table:
[in this window]
[in a new window]

 
TABLE 1. Findings at Percutaneous Breast Biopsy in Accordance with Institution
 
Different institutions had variable criteria for selecting lesions for biopsy, guidance methods, numbers of specimens per lesion, numbers of histologic slides evaluated per lesion, numbers of skin entry sites, and commencement and termination dates. Lesions at each institution were accrued sequentially. Ultrasonographically (US) guided percutaneous biopsy findings were not studied.

For each lesion in the study group, patient, lesion, and procedural variables were coded. These variables were summarized and compared in different analyses. To the extent that some of these variables were correlated, statistical tests in this study were not performed independently. The only patient variable was age at time of biopsy. Mammographic lesion variables were maximum lesion diameter and lesion type (microcalcifications [without masses] or masses). Masses included asymmetric densities, areas of architectural distortion, and other space-occupying lesions, with or without associated calcifications. Procedural variables were biopsy device (large core or vacuum assisted), vacuum-assisted biopsy probe size (14- or 11-gauge), and number of specimens obtained per lesion. All large-core biopsies were performed with a variety of 14-gauge cutting needles and a variety of automated "guns" that were not coded. All vacuum-assisted biopsies were performed with 14- or 11-gauge probes by using the Mammotome biopsy device (Biopsys Medical/Ethicon Endo-Surgery, Cincinnati, Ohio). Other vacuum-assisted biopsy devices were available but not studied.

Two biopsy tables were used: The Mammotest (Fischer Imaging, Denver, Colo) was used exclusively at 12 institutions; the StereoGuide (LoRad Medical Systems, Danbury, Conn), at three institutions; and both tables, at one institution. Biopsy was performed in a total of 1,106 lesions by using Fischer tables and in 220 lesions by using LoRad tables.

Biopsy techniques involving large-core (15,1723) and vacuum-assisted (15,2124) devices have been described. At large-core biopsy, a separate needle insertion is required for each tissue specimen. At vacuum-assisted biopsy, a single probe insertion is required, and the probe is rotated to obtain successive tissue specimens.

Surgical histologic diagnoses of invasive breast carcinoma with or without associated DCIS were called "underestimations"; all other surgical histologic diagnoses were called "agreements" (9). Surgical diagnoses of high-risk (such as atypical ductal hyperplasia [ADH]) or benign lesions were considered agreements and implied that there had been percutaneous removal of the DCIS. The underestimation rate was determined by dividing the number of lesions percutaneously diagnosed as DCIS and subsequently excised into the number of those lesions found at surgery to be invasive carcinoma. The size of the invasive carcinoma and the types and number of surgeries per lesion were not coded.

Data were collected with a variety of software systems at the 16 participating institutions. All data were transferred to a single spreadsheet (EXCEL; Microsoft, Redmond, Wash) for data consolidation and then to a statistical analysis program (STATVIEW; Abacus Concepts, Berkeley, Calif). A P value of less than .05 was considered to indicate a significant difference. All P values were calculated by using the Fisher exact method. The {chi}2 test was performed to compare mammographic lesion type and underestimation rates. The Student t test was performed to compare patient ages, lesion sizes, and the numbers of samples obtained per lesion.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Of all the lesions biopsied, 61% (8,306 of 13,640) were microcalcification lesions and 39% (5,334 of 13,640) were mass lesions. DCIS lesions on which surgery was subsequently performed were found in 14.2% (1,182 of 8,306) of microcalcification lesions and in 2.7% (144 of 5,334) of mass lesions. This finding can be expressed differently: For DCIS lesions on which surgery was subsequently performed, 89% (1,182 of 1,326) were microcalcifications and 11% (144 of 1,326) were masses. Thus, DCIS is more likely to be diagnosed at biopsy of a microcalcification lesion than at biopsy of a mass lesion.

The DCIS underestimation rate was 11% (38 of 348) of lesions diagnosed at 14-gauge vacuum-assisted biopsy and 11% (69 of 605) of lesions diagnosed at 11-gauge vacuum-assisted biopsy. Because no significant difference was found in the underestimation rates for the 14- and 11-gauge vacuum-assisted probes (P > .9), data for these two techniques were combined throughout the study. Patient, lesion, and procedural variables for large-core and vacuum-assisted devices were compared (Table 2). No significant differences were found between the groups of patients who underwent stereotactic biopsy with the large-core and vacuum-assisted devices on the basis of patient age at the time of percutaneous biopsy (P > .45) or of maximum mammographic lesion diameter (P > .93) (Table 2). The mean number of specimens obtained per lesion was 39% more at vacuum-assisted biopsy than at large-core biopsy (Table 2). In lesions in which biopsy was performed, the percentage of microcalcification lesions, as compared with that of mass lesions, was significantly higher at vacuum-assisted than at large-core biopsy (P < .008) (Table 2). Data were not available for the maximum lesion diameter in 39 lesions nor for the number of specimens obtained per lesion in 25 lesions; these data were excluded from their respective analyses.


View this table:
[in this window]
[in a new window]

 
TABLE 2. Patient, Lesion, and Procedural Variables in Lesions Diagnosed as DCIS at Percutaneous Breast Biopsy
 
At subsequent surgical biopsy, DCIS was proved to be invasive carcinoma in 20.4% (76 of 373) of lesions diagnosed at large-core biopsy and in 11.2% (107 of 953) of lesions diagnosed at vacuum-assisted biopsy (P < .001, {chi}2 test) (Table 2).

The data in Table 3 demonstrate that, in descending order of importance, lesion type, biopsy device, and number of specimens obtained per lesion each had a significant effect on DCIS underestimation rates. DCIS underestimations according to lesion type were 1.9 times more frequent in masses than in microcalcifications; according to biopsy device, 1.8 times more frequent with large-core devices than with vacuum-assisted devices; and according to number of specimens obtained per lesion, 1.5 times more frequent with 10 or fewer specimens than with more than 10.


View this table:
[in this window]
[in a new window]

 
TABLE 3. DCIS and ADH Underestimation Rates: Comparison of Three Variables
 
To be unbiased, the DCIS underestimation rates for the two biopsy devices must be compared by using the two other significant variables—lesion type and number of specimens obtained per lesion. Otherwise, it would not be known whether any difference seen in underestimation rates between biopsy devices was the direct result of a difference in the performance of the devices themselves or of a difference in lesion type and/or number of specimens obtained.

The data in Table 4 demonstrate that for mass and microcalcification lesions, the underestimation rate was lower for the vacuum-assisted device than for the large-core device. This was true whether the number of specimens obtained per lesion was 10 or fewer or greater than 10. That is, there was a consistent difference in the performance of the biopsy devices that was independent of the type of lesion in which biopsy was performed or the number of specimens obtained per lesion.


View this table:
[in this window]
[in a new window]

 
TABLE 4. Biopsy Device DCIS Underestimation Rates, Controlled for Lesion Type and Number of Specimens
 
The data also demonstrate two interesting stereotactic procedural observations for DCIS lesions. First, as maximum lesion diameter increased, more specimens were obtained. By using a no-intercept least-squares model, one additional specimen was obtained for every 2 mm of increase in maximum lesion diameter (r = 0.63, P < .001). Second, more specimens were obtained in microcalcifications than in mass lesions at large-core biopsy but not at vacuum-assisted biopsy (Table 5).


View this table:
[in this window]
[in a new window]

 
TABLE 5. Number of Specimens per Lesion by Biopsy Device and Lesion Type
 
DCIS underestimation rates also were a function of maximum lesion diameter. Underestimation rates were 11.9% (98 of 823) for lesions 1–10 mm, 14.6% (43 of 295) for lesions 11–20 mm, and 21.9% (37 of 169) for lesions greater than or equal to 21 mm in maximum diameter (P < .003, {chi}2 test). As shown in the Figure, the underestimation rates in each size category were higher for the large-core device than for the vacuum-assisted device. When biopsy device was compared with lesion diameter, DCIS underestimations at large-core biopsy, as compared with those at vacuum-assisted biopsy, are 1.8 times more frequent in 1–10-mm lesions, 2.3 times more frequent in 11–20-mm lesions, and 1.2 times more frequent in lesions greater than or equal to 21 mm.



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1. Bar graph shows significantly lower underestimation rates for biopsies performed with a vacuum-assisted device, as compared with those performed with a large-core device in lesions with a maximum diameter of 1-10-mm (P < .004) or 11-20 mm (P < .006) but not for lesions with a maximum diameter of 21 mm or greater (P > .5).

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The diagnosis of DCIS at stereotactic 14-gauge large-core biopsy, performed in patients in the prone position, of nonpalpable breast lesions underestimates the presence of invasive breast cancer (found at the same site at subsequent surgery) in 15%–36% of lesions (18) (Table 6). In limited data, the underestimation rates at vacuum-assisted biopsy were 0%–19% (4,7,8,26,27) (Table 6). To our knowledge, it has been impossible to independently measure the effect of biopsy device, lesion type, and number of specimens per lesion in small sample sizes (2,4,7,8, 26,27).


View this table:
[in this window]
[in a new window]

 
TABLE 6. DCIS Underestimation Rates: Comparison of Three Biopsy Techniques
 
Assuming equal accuracy of needle or probe positioning in the breast and histologic evaluation of resected tissue, we anticipate that a more aggressive percutaneous biopsy technique would result in a lower DCIS underestimation rate. The vacuum-assisted probes remove more tissue per specimen than the large-core needles: By averaging the results in recent studies (16,28,29), the weight per individual specimen was 95 mg at 11-gauge vacuum-assisted biopsy, 37 mg at 14-gauge vacuum-assisted biopsy, and 17 mg at 14-gauge large-core biopsy. These findings parallel the removal rate of histologically benign lesions: As evaluated at initial mammography after biopsy, no residual lesion was identified in 64% (96 of 150) of the 11-gauge vacuum-assisted biopsies, in 22% (21 of 95) of the 14-gauge vacuum-assisted biopsies, and in 9% (40 of 422) of the 14-gauge large-core biopsies (30).

We found the DCIS underestimation rate of lesions diagnosed at vacuum-assisted biopsy, 11.2% (107 of 953), to be lower than that of lesions diagnosed at 14-gauge large-core biopsy, 20.4% (76 of 373). By using the vacuum-assisted device, the greater weight per specimen and higher removal rate of lesions in which biopsy was performed suggested that the 11-gauge probe would produce a lower DCIS underestimation rate than would the 14-gauge probe. Instead, we found that both probes had an 11% DCIS underestimation rate. This lack of difference is difficult to understand. Although we found no difference between the probes as judged by using patient age and lesion type and size, we do know that, at seven of the 16 institutions, the 11-gauge probe was selectively rather than universally used once it became available. Perhaps selection bias according to lesion proximity to the chest wall and/or skin, lesion conspicuity, breast size, patient cooperation, and/or other factors that might have affected biopsy accuracy played a role. As an alternative, more tissue than we obtained with the 11-gauge probe or histologic evaluation of more slides from 11-gauge biopsy may be required to further reduce the DCIS underestimation rate.

The number of specimens per lesion, mean weight per individual specimen, and number of histologic slides evaluated from the paraffin block that contained the collective specimens all presumably affect the accuracy of diagnosis at 14- and 11-gauge vacuum-assisted biopsy. In recent studies (16,28,29), the individual mean specimen weight of 95 mg at 11-gauge biopsy was 2.6 times that of 37 mg at 14-gauge biopsy. By assuming an equal number of specimens per lesion, much of the expected 11-gauge-biopsy benefit might be lost if only three slides are obtained from the paraffin block. By assuming that slides are obtained at three equally spaced levels, the calculated surface area for three levels from one cylindrical specimen the size of the tissue collection bowl near the end of the probe is approximately 106 mm2 at 11-gauge biopsy, which is 1.3 times the approximate 80 mm2 at 14-gauge biopsy. If one instead obtains slides at equal depths of 0.4 mm, one obtains the same three slides at 14-gauge biopsy but five slides at 11-gauge biopsy. Those five 11-gauge biopsy slides will have a surface area of approximately 170 mm2, which is 2.1 times the 80 mm2 of the three 14-gauge biopsy slides. It will be interesting to see whether obtaining slides at equal depths in a specimen rather than an equal number of slides per specimen does increase the accuracy of diagnosis at 11-gauge biopsy.

We found the DCIS underestimation rate to be lower with the vacuum-assisted device than with the large-core device in masses and microcalcifications. With each type of lesion, the accuracy of the vacuum-assisted device was increased whether the number of specimens per lesion was 10 or fewer or more than 10 (Table 4). We found a tendency to obtain more specimens from larger lesions. In some of the larger lesions, two or more skin entry sites may be necessary to adequately sample the lesion. The Figure shows that use of the vacuum-assisted device resulted in fewer underestimations for lesions of all sizes, but the improved accuracy for lesions greater than or equal to 21 mm in maximum diameter was minimal and not significant. This suggests that larger lesions need even more thorough tissue sampling. We suspect that sampling should be performed by using more skin entry sites rather than by obtaining more samples from the same site. "The goal in this sampling strategy is to obtain samples at uniform distances throughout the lesion so that representative material is obtained for all aspects of the lesion" (23).

ADH "histologic underestimations" (9) (ie, detection of carcinoma at the same site at a subsequent surgery) also occur at stereotactic breast biopsy (1,37,25,26,3142). There are some interesting similarities between DCIS underestimation rates in the current study and ADH underestimation rates in a previous study (25), in which 14-gauge stereotactic biopsy procedures with large-core and vacuum-assisted devices were compared.

Table 3 demonstrates the ADH and DCIS underestimation rates for the same three variables. In both cases, underestimations were more likely in mass lesions than in microcalcification lesions, in lesions in which biopsy was performed with the large-core device than in those in which biopsy was performed with the vacuum-assisted device, and with 10 or fewer specimens per lesion rather than with greater than 10 specimens per lesion.

DCIS underestimations are also known to occur at percutaneous biopsy in which the Advanced Breast Biopsy Instrumentation device (United States Surgical, Norwalk, Conn) (43) is used and at needle-localized surgical biopsy (44,45). Until lesions diagnosed as DCIS with those more interventional types of biopsy are routinely subjected to repeat excision, the DCIS underestimation rates will not be known.

A cost analysis of the various breast biopsy methods was beyond the scope of this study; DCIS underestimations are but one small component of such an analysis. In addition to the cost of the initial biopsy, which includes equipment and supplies, the prevalence of carcinoma at biopsy, false-positive and false-negative rates, ADH underestimation rate, mammographic and histologic discordance rate, repeat biopsy rate, percentage of malignancies treated with two-stage surgery, and follow-up methods are among the factors to be considered when deciding which biopsy methods are the most cost-effective. Because lesions in which biopsy is performed have variable characteristics, which include palpability, size, type (microcalcification vs mass), breast imaging reporting and data system assessment categories (46), and depiction with various imaging modalities (eg, mammography, US, and magnetic resonance imaging), we presume that there will not be a universally cost-effective biopsy method that is best for all lesions.

In conclusion, DCIS underestimations were 1.9 times more likely in masses than in microcalcifications, 1.8 times more likely with a large-core device than with a vacuum-assisted device, and 1.5 times more likely if the number of specimens obtained per lesion was 10 or fewer rather than greater than 10. The DCIS underestimation rate was unexpectedly just as high at vacuum-assisted biopsy with 11-gauge probes as at biopsy with 14-gauge probes. DCIS underestimation rates increased as the maximum lesion diameter increased.


    ACKNOWLEDGMENTS
 
We thank Julie C. Clark, BA, for precise manuscript preparation.


    FOOTNOTES
 
Abbreviations: ADH = atypical ductal hyperplasia, DCIS = ductal carcinoma in situ

Author contributions: Guarantors of integrity of entire study, R.J.J., F.B.; study concepts, all authors; study design, R.J.J., F.B.; definition of intellectual content, R.J.J., F.B.; literature research, R.J.J., F.B.; clinical studies, all authors; data acquisition, all authors; data analysis, R.J.J., F.B.; statistical analysis, F.B.; manuscript preparation, R.J.J., F.B.; manuscript editing and review, all authors.

  R.J.J. and W.P.E. are former shareholders in and former clinical consultants to Biopsys Medical. F.B., S.H.P., W.P.E., T.R.R., A.A.S., K.J.S., and A.B.W. are shareholders in Johnson & Johnson.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Jackman RJ, Nowels KW, Shepard MJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994; 193:91-95.[Abstract/Free Full Text]
  2. Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology 1995; 194:379-381.[Abstract/Free Full Text]
  3. Nguyen M, McCombs MM, Ghandehari S, et al. An update on core needle biopsy for radiologically detected breast lesions. Cancer 1996; 78:2340-2345.[Medline]
  4. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997; 202:843-847.[Abstract/Free Full Text]
  5. Acheson MB, Patton RG, Howisey RL, Lane RF, Morgan A. Histologic correlation of image-guided core biopsy with excisional biopsy of nonpalpable breast lesions. Arch Surg 1997; 132:815-821.[Abstract/Free Full Text]
  6. Fuhrman GM, Cederbom GJ, Bolton JS, et al. Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. Ann Surg 1998; 6:932-939.
  7. Meyer JE, Smith DN, Lester SC, et al. Large-core needle biopsy of nonpalpable breast lesions. JAMA 1999; 181:1638-1641.
  8. Won B, Reynolds HE, Lazaridis CL, Jackson VP. Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease. AJR Am J Roentgenol 1999; 173:227-229.[Abstract/Free Full Text]
  9. Burbank F, Parker SH. Methods for evaluating the quality of an image-guided breast biopsy program. Semin Breast Dis 1998; 1:71-83.
  10. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982; 50:1309-1314.[Medline]
  11. Silverstein MJ, Rosser RJ, Gierson ED, et al. Axillary lymph node dissection for intraductal breast carcinoma: is it indicated?. Cancer 1987; 59:1819-1824.[Medline]
  12. Wood WC. Should axillary dissection be performed in patients with DCIS? (editorial). Ann Surg Oncol 1995; 2:193-194.[Medline]
  13. Pandelidis SM, Peters KL, Walusimbi MS, et al. The role of axillary dissection in mammographically detected carcinoma. J Am Coll Surg 1997; 184:341-345.[Medline]
  14. Morrow M. Axillary dissection: an obsolete operation?. Breast J 1998; 4:330-335.
  15. Parker SH, Burbank F. A practical approach to minimally invasive breast biopsy. Radiology 1996; 200:11-20.[Abstract/Free Full Text]
  16. Burbank F, Parker SH, Fogarty TJ. Stereotactic breast biopsy: improved tissue harvesting with the Mammotome. Am Surg 1996; 62:738-744.[Medline]
  17. Parker SH, Lovin JD, Jobe WE, et al. Stereotactic breast biopsy with a biopsy gun. Radiology 1990; 176:741-747.[Abstract/Free Full Text]
  18. Parker SH, Lovin JD, Jobe WE, Burke BJ, Hopper KD, Yakes WR. Nonpalpable breast lesions: stereotactic automated large-core biopsies. Radiology 1991; 180:403-407.[Abstract/Free Full Text]
  19. Elvecrog EL, Lechner MC, Nelson MT. Nonpalpable breast lesions: correlation of stereotaxic large-core needle biopsy and surgical biopsy results. Radiology 1993; 188:453-455.[Abstract/Free Full Text]
  20. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: how many core specimens are needed?. Radiology 1994; 192:793-795.[Abstract/Free Full Text]
  21. Parker SH, Dennis MA, Stavros AT. Critical pathways in percutaneous breast intervention. RadioGraphics 1995; 15:946-950.[Medline]
  22. Parker SH, Stavros AT, Dennis MA. Needle biopsy techniques. Radiol Clin North Am 1995; 33:1171-1186.[Medline]
  23. Burbank F. Stereotactic breast biopsy: its history, its present, and its future. Am Surg 1996; 62:128-150.[Medline]
  24. Parker SH, Klaus AJ. Performing a breast biopsy with a directional, vacuum-assisted biopsy instrument. RadioGraphics 1997; 17:1233-1252.[Abstract]
  25. Jackman RJ, Burbank F, Parker SH, et al. Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy. Radiology 1997; 204:485-488.[Abstract/Free Full Text]
  26. Liberman L, Smolkin JH, Dershaw DD, Morris EA, Abramson AF, Rosen PP. Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy. Radiology 1998; 208:251-260.[Abstract/Free Full Text]
  27. Liberman L, Vuolo M, Dershaw DD, et al. Epithelial displacement after stereotactic 11-gauge directional vacuum-assisted breast biopsy. AJR Am J Roentgenol 1999; 172:677-681.[Abstract/Free Full Text]
  28. Burbank F. Stereotactic breast biopsy: comparison of 14- and 11-gauge Mammotome probe performance and complication rates. Am Surg 1997; 63:988-995.[Medline]
  29. Berg WA, Krebs TL, Campassi C, Magder LS, Sun CCJ. Evaluation of 14- and 11-gauge directional, vacuum-assisted biopsy probes and 14-gauge biopsy guns in a breast parenchymal model. Radiology 1997; 205:203-208.[Abstract/Free Full Text]
  30. Jackman RJ, Marzoni FA, Nowels KW. Percutaneous removal of benign mammographic lesions: comparison of automated large-core and directional vacuum-assisted stereotactic biopsy techniques. AJR Am J Roentgenol 1998; 171:1325-1330.[Abstract/Free Full Text]
  31. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. AJR Am J Roentgenol 1995; 164:1111-1113.[Abstract/Free Full Text]
  32. Dahlstrom JE, Jain S, Sutton T, Sutton S. Diagnostic accuracy of stereotactic core biopsy in a mammographic breast cancer screening programme. Histopathology 1996; 28:421-427.[Medline]
  33. Tocino I, Garcia BM, Carter D. Surgical biopsy findings in patients with atypical hyperplasia diagnosed by stereotaxic core needle biopsy. Ann Surg Oncol 1996; 3:483-488.[Abstract]
  34. Moore MM, Hargett CW, Hanks JB, et al. Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. Ann Surg 1997; 225:726-733.[Medline]
  35. Gadzala DE, Cederbom GJ, Bolton JS, et al. Appropriate management of atypical ductal hyperplasia diagnosed by stereotactic core needle breast biopsy. Ann Surg Oncol 1997; 4:283-286.[Abstract]
  36. Brown TA, Wall JW, Christensen ED, et al. Atypical hyperplasia in the era of stereotactic core needle biopsy. J Surg Oncol 1998; 67:168-173.[Medline]
  37. Lee CH, Egglin TK, Philpotts L, Mainiero MB, Tocino I. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. Radiology 1997; 202:849-854.[Abstract/Free Full Text]
  38. Liberman L, Dershaw DD, Glassman JR, et al. Analysis of cancers not diagnosed at stereotactic core breast biopsy. Radiology 1997; 203:151-157.[Abstract/Free Full Text]
  39. Meyer JE, Smith DN, Lester SC, et al. Large-needle core biopsy: nonmalignant breast abnormalities evaluated with surgical excision or repeat core biopsy. Radiology 1998; 206:717-720.[Abstract/Free Full Text]
  40. Lin PH, Clyde JC, Bates DM, Garcia JM, Matsumoto GH, Girvin GW. Accuracy of stereotactic core-needle breast biopsy in atypical ductal hyperplasia. Am J Surg 1998; 175:380-382.[Medline]
  41. Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni FA, Finkelstein SI, Shepard MJ. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999; 210:799-805.[Abstract/Free Full Text]
  42. Brem RF, Behrndt VS, Sanow L, Gatewood OMB. Atypical ductal hyperplasia: histologic underestimation of carcinoma in tissue harvested from impalpable breast lesions using 11-gauge stereotactically guided directional vacuum-assisted biopsy. AJR Am J Roentgenol 1999; 172:1405-1407.[Abstract/Free Full Text]
  43. Matthews BD, Williams GB. Initial experience with the Advanced Breast Biopsy Instrumentation system. Am J Surg 1999; 177:97-101.[Medline]
  44. Thompson WR, Bowen JR, Dorman BA, Pricolo VE, Shahinian TK, Soderberg CH. Mammographic localization and biopsy of nonpalpable breast lesions: a 5-year study. Arch Surg 1991; 126:730-734.[Abstract/Free Full Text]
  45. Tartter PI, Bleiweiss IJ, Levchenko S. Factors associated with clear biopsy margins and clear reexcision margins in breast cancer specimens from candidates for breast conservation. J Am Coll Surg 1997; 185:268-273.[Medline]
  46. American College of Radiology. Breast imaging reporting and data system (BI-RADS) 3rd ed. Reston, Va: American College of Radiology, 1998.



This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
B Doyle, M Al-Mudhaffer, M M Kennedy, A O'Doherty, F Flanagan, E W McDermott, M J Kerin, A D Hill, and C M Quinn
Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: is it justified?
J. Clin. Pathol., June 1, 2009; 62(6): 534 - 538.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
R. J. Jackman, F. A. Marzoni Jr., and J. Rosenberg
False-Negative Diagnoses at Stereotactic Vacuum-Assisted Needle Breast Biopsy: Long-Term Follow-Up of 1,280 Lesions and Review of the Literature
Am. J. Roentgenol., February 1, 2009; 192(2): 341 - 351.
[Abstract] [Full Text] [PDF]


Home page
Am J Clin PatholHome page
M. J. Wagoner, C. Laronga, and G. Acs
Extent and Histologic Pattern of Atypical Ductal Hyperplasia Present on Core Needle Biopsy Specimens of the Breast Can Predict Ductal Carcinoma In Situ in Subsequent Excision
Am J Clin Pathol, January 1, 2009; 131(1): 112 - 121.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
M. Jang, N. Cho, W. K. Moon, J. S. Park, M. H. Seong, and I. A. Park
Underestimation of Atypical Ductal Hyperplasia at Sonographically Guided Core Biopsy of the Breast
Am. J. Roentgenol., November 1, 2008; 191(5): 1347 - 1351.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. R. Porembka, R. L. Abraham, J. A. Sefko, A. D. Deshpande, D. B. Jeffe, and J. A. Margenthaler
Factors Associated with Lymph Node Assessment in Ductal Carcinoma in situ: Analysis of 1988-2002 Seer Data
Ann. Surg. Oncol., October 1, 2008; 15(10): 2709 - 2719.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
G. Schueller, S. Jaromi, L. Ponhold, M. Fuchsjaeger, M. Memarsadeghi, M. Rudas, M. Weber, L. Liberman, and T. H. Helbich
US-guided 14-gauge Core-Needle Breast Biopsy: Results of a Validation Study in 1352 Cases
Radiology, August 1, 2008; 248(2): 406 - 413.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. Samphao, J. M. Eremin, M. El-Sheemy, and O. Eremin
Management of the Axilla in Women With Breast Cancer: Current Clinical Practice and a New Selective Targeted Approach
Ann. Surg. Oncol., May 1, 2008; 15(5): 1282 - 1296.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
H. J. Shin, H. H. Kim, S. M. Kim, H. R. Yang, J.-H. Sohn, G. Y. Kwon, and G. Gong
Papillary Lesions of the Breast Diagnosed at Percutaneous Sonographically Guided Biopsy: Comparison of Sonographic Features and Biopsy Methods
Am. J. Roentgenol., March 1, 2008; 190(3): 630 - 636.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
R. F. Brem, M. C. Lechner, R. J. Jackman, J. A. Rapelyea, W. P. Evans, L. E. Philpotts, J. Hargreaves, and S. Wasden
Lobular Neoplasia at Percutaneous Breast Biopsy: Variables Associated with Carcinoma at Surgical Excision
Am. J. Roentgenol., March 1, 2008; 190(3): 637 - 641.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
A. P. Lourenco, M. B. Mainiero, E. Lazarus, D. Giri, and B. Schepps
Stereotactic Breast Biopsy: Comparison of Histologic Underestimation Rates with 11- and 9-Gauge Vacuum-Assisted Breast Biopsy
Am. J. Roentgenol., November 1, 2007; 189(5): W275 - W279.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
S. Pandey, M. J. Kornstein, W. Shank, and E. S. de Paredes
Columnar Cell Lesions of the Breast: Mammographic Findings with Histopathologic Correlation
RadioGraphics, October 1, 2007; 27(suppl_1): S79 - S89.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
H. S. Cody III
Sentinel Lymph Node Biopsy for DCIS: Are We Approaching Consensus?
Ann. Surg. Oncol., August 1, 2007; 14(8): 2179 - 2181.
[Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J.-m. Lee, J. B. Kaplan, M. P. Murray, M. Mazur-Grbec, T. Tadic, D. Stimac, and L. Liberman
Underestimation of DCIS at MRI-Guided Vacuum-Assisted Breast Biopsy
Am. J. Roentgenol., August 1, 2007; 189(2): 468 - 474.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M F Dillon, C M Quinn, E W McDermott, A O'Doherty, N O'Higgins, and A D K Hill
Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice.
J. Clin. Pathol., July 1, 2006; 59(7): 740 - 743.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
W. W. M. Lam, W. C. W. Chu, A. P. Y. Tang, G. Tse, and T. K. F. Ma
Role of Radiologic Features in the Management of Papillary Lesions of the Breast.
Am. J. Roentgenol., May 1, 2006; 186(5): 1322 - 1327.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
R. J. Jackman and J. Rodriguez-Soto
Breast microcalcifications: retrieval failure at prone stereotactic core and vacuum breast biopsy--frequency, causes, and outcome.
Radiology, April 1, 2006; 239(1): 61 - 70.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. K. Koskela, M. Sudah, M. H. Berg, V. J. Karja, P. K. Mustonen, V. Kataja, and R. S. Vanninen
Add-on Device for Stereotactic Core-Needle Breast Biopsy: How Many Biopsy Specimens Are Needed for a Reliable Diagnosis?
Radiology, September 1, 2005; 236(3): 801 - 809.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
V. Doridot, M. Meunier, C. E. Khoury, C. Nos, A. Vincent-Salomon, B. Sigal-Zafrani, and K. B. Clough
Stereotactic Radioguided Surgery by SiteSelect for Subclinical Mammographic Lesions
Ann. Surg. Oncol., February 1, 2005; 12(2): 181 - 188.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
F. R. Margolin, L. Kaufman, R. P. Jacobs, S. R. Denny, and J. D. Schrumpf
Stereotactic Core Breast Biopsy of Malignant Calcifications: Diagnostic Yield of Cores with and Cores without Calcifications on Specimen Radiographs
Radiology, October 1, 2004; 233(1): 251 - 254.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
F. M. Lomoschitz, T. H. Helbich, M. Rudas, G. Pfarl, K. F. Linnau, A. Stadler, and R. J. Jackman
Stereotactic 11-gauge Vacuum-assisted Breast Biopsy: Influence of Number of Specimens on Diagnostic Accuracy
Radiology, September 1, 2004; 232(3): 897 - 903.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Morrow
The Certainties and the Uncertainties of Ductal Carcinoma In Situ
J Natl Cancer Inst, March 17, 2004; 96(6): 424 - 425.
[Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
P. C. Stomper, J. Geradts, S. B. Edge, and E. G. Levine
Mammographic Predictors of the Presence and Size of Invasive Carcinomas Associated With Malignant Microcalcification Lesions Without a Mass
Am. J. Roentgenol., December 1, 2003; 181(6): 1679 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
F. R. Margolin, L. Kaufman, S. R. Denny, R. P. Jacobs, and J. D. Schrumpf
Metallic Marker Placement After Stereotactic Core Biopsy of Breast Calcifications: Comparison of Two Clips and Deployment Techniques
Am. J. Roentgenol., December 1, 2003; 181(6): 1685 - 1690.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. R. McCready
Quality Assurance: The Value of Data and the Will to Improve
Ann. Surg. Oncol., October 1, 2003; 10(8): 837 - 838.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
L. E. Hoorntje, M. E. I. Schipper, P. H. M. Peeters, F. Bellot, R. K. Storm, and I. H. M. Borel Rinkes
The Finding of Invasive Cancer After a Preoperative Diagnosis of Ductal Carcinoma-In-Situ: Causes of Ductal Carcinoma-In-Situ Underestimates With Stereotactic 14-Gauge Needle Biopsy
Ann. Surg. Oncol., August 1, 2003; 10(7): 748 - 753.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
M. S. Soo, J. A. Baker, and E. L. Rosen
Sonographic Detection and Sonographically Guided Biopsy of Breast Microcalcifications
Am. J. Roentgenol., April 1, 2003; 180(4): 941 - 948.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. Pandelidis, D. Heilman, D. Jones, K. Stough, J. Trapeni, and Y. Suliman
Accuracy of 11-Gauge Vacuum-Assisted Core Biopsy of Mammographic Breast Lesions
Ann. Surg. Oncol., January 1, 2003; 10(1): 43 - 47.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
S. S. Sonnad
Describing Data: Statistical and Graphical Methods
Radiology, December 1, 2002; 225(3): 622 - 628.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
G. Pfarl, T. H. Helbich, C. C. Riedl, T. Wagner, M. Gnant, M. Rudas, and L. Liberman
Stereotactic 11-Gauge Vacuum-Assisted Breast Biopsy: A Validation Study
Am. J. Roentgenol., December 1, 2002; 179(6): 1503 - 1507.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
E. L. Rosen, R. C. Bentley, J. A. Baker, and M. S. Soo
Imaging-Guided Core Needle Biopsy of Papillary Lesions of the Breast
Am. J. Roentgenol., November 1, 2002; 179(5): 1185 - 1192.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
L. Liberman, J. B. Kaplan, E. A. Morris, A. F. Abramson, J. H. Menell, and D. D. Dershaw
To Excise or To Sample the Mammographic Target: What Is the Goal of Stereotactic II-Gauge Vacuum-Assisted Breast Biopsy?
Am. J. Roentgenol., September 1, 2002; 179(3): 679 - 683.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
R. J. Jackman, R. L. Birdwell, and D. M. Ikeda
Atypical Ductal Hyperplasia: Can Some Lesions Be Defined as Probably Benign after Stereotactic 11-gauge Vacuum-assisted Biopsy, Eliminating the Recommendation for Surgical Excision?
Radiology, August 1, 2002; 224(2): 548 - 554.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
P. Wunderbaldinger, G. Wolf, K. Turetschek, and T. H. Helbich
Comparison of Sitting Versus Prone Position for Stereotactic Large-Core Breast Biopsy in Surgically Proven Lesions
Am. J. Roentgenol., May 1, 2002; 178(5): 1221 - 1225.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
L. Liberman, S. L. Goodstine, D. D. Dershaw, E. A. Morris, L. R. LaTrenta, A. F. Abramson, and K. J. V. Zee
One Operation After Percutaneous Diagnosis of Nonpalpable Breast Cancer: Frequency and Associated Factors
Am. J. Roentgenol., March 1, 2002; 178(3): 673 - 679.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. A. Perez-Fuentes, I. R. Longobardi, V. F. Acosta, C. E. Marin, and L. Liberman
Sonographically Guided Directional Vacuum-Assisted Breast Biopsy: Preliminary Experience in Venezuela
Am. J. Roentgenol., December 1, 2001; 177(6): 1459 - 1463.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
W. A. Berg, C. L. Arnoldus, E. Teferra, and M. Bhargavan
Biopsy of Amorphous Breast Calcifications: Pathologic Outcome and Yield at Stereotactic Biopsy
Radiology, November 1, 2001; 221(2): 495 - 503.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackman, R. J.
Right arrow Articles by Adler, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackman, R. J.
Right arrow Articles by Adler, S. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE